33
Participants
Start Date
February 18, 2023
Primary Completion Date
February 18, 2025
Study Completion Date
February 18, 2026
EP/EC+PD-1
Toripalimab 240 mg, administered on the first day of each cycle, and a cycle of administration every 3 weeks. Etoposide 100mg/m2, d1-3, cisplatin 25mg/m2, d1-3 or carboplatin AUC=5 d1, administered on the first day of each cycle, a cycle of administration every 3 weeks. Toripalimab combined with etoposide and cisplatin/carboplatin was used for 4 to 6 courses of treatment.
RECRUITING
Sun Yat-sen University cancer center, Guangzhou
Sun Yat-sen University
OTHER